A court hands Lilly an early loss against a compounding pharmacy

A federal judge in Florida has dealt Eli Lilly an early loss in its legal campaign against compounding pharmacies selling versions of tirzepatide, the active ingredient in Lilly's Mounjaro and Zepbound. On Tuesday, April 9, U.S. District Judge Roy Altman dismissed Lilly's case against RXCompoundStore.com, finding that the company could not use Florida state law to block the pharmacy from selling its own compounded tirzepatide product ^[1].

In his ruling, Altman wrote that Lilly was effectively trying to enforce the federal Food, Drug, and Cosmetic Act (FDCA) through a state-law lawsuit, a job the law reserves almost entirely for the FDA ^[1]. "We think Eli Lilly is using state law to enforce the terms of the FDCA … which … is a task generally 'reserve[d] to the FDA,'" the judge wrote, adding that courts will not let Lilly "use state law as a back door to private[ly] enforce the FDCA" ^[1]. He also cited the U.S. Supreme Court's finding that "the FDCA and its regulations provide the United States with nearly exclusive enforcement authority" ^[1].

Lilly had filed suit against RXCompoundStore.com and other compounding pharmacies, medical spas and wellness centers in September 2023, arguing that these businesses were violating the FDCA by selling altered versions of tirzepatide that the FDA has not approved ^[1]. Compounded drugs are medicines that pharmacies chemically alter or combine with other ingredients; they can have different safety, tolerability and effectiveness than the original approved drug, and the FDA cannot vouch for their quality, though such compounding is allowed in some narrow situations, such as when a patient is allergic to an ingredient in the approved product ^[1]. At the time it filed suit, Lilly said the compounded products could pose health risks and that its lawsuits were meant to "protect patient safety and stop the unlawful marketing and sale of non-FDA approved compounded products" ^[1].

Lilly is not alone in this fight. Novo Nordisk, which makes semaglutide products Ozempic and Wegovy, has filed at least two rounds of lawsuits, in June and July 2023, against compounders and clinics selling altered semaglutide ^[1]. Novo notched an early win of its own in February 2024, when a Miami federal court issued a permanent injunction against a company called Ekzotika Corporation, barring it from suggesting its compounded semaglutide products were genuine or FDA-approved ^[1].

Why it matters for patients

This ruling does not mean compounded tirzepatide is safe, effective, or legal in every circumstance — the judge's decision was about which law applies and who can enforce it, not about the quality of the products themselves ^[1]. For patients, it signals that Lilly's broader legal strategy against compounders may increasingly hinge on specific claims, such as false advertising or misleading safety statements, rather than a blanket effort to stop compounding of tirzepatide outright ^[1]. Novo Nordisk's parallel win against Ekzotika suggests that lawsuits targeting deceptive marketing — claiming a compounded product is authentic or FDA-approved when it is not — may have more traction in court than lawsuits aimed at the underlying compounding practice itself ^[1]. Patients weighing compounded versions of these drugs should understand that the FDA does not review or guarantee the quality of compounded medications, and the legal status of individual pharmacies and products can vary and may change as these cases continue ^[1].

What happens next

The sources reviewed do not specify Lilly's next steps following this dismissal, nor do they indicate whether the company plans to appeal or refile claims on different legal grounds. It is also not yet known how this ruling might affect Lilly's other pending lawsuits against additional compounding pharmacies and wellness centers filed in September 2023 ^[1].